Grünenthal announced today that the company successfully concluded a Phase I trial evaluating the safety and tolerability of its proprietary NOP agonist. In the trial, which involved 113 healthy ...
The company says Sol matches competing systems like Mythos Preview while using only a third of the output tokens. OpenAI has announced a limited preview of its new GPT-5.6 model lineup, introducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results